John W. Cox serves as counsel in the Intellectual Property Litigation Group. John is a registered patent attorney whose practice focuses on patent litigation and strategic counseling, primarily in the pharmaceutical and chemical arts. John practices in all aspects of district court patent litigation, but has specialized legal expertise with cases involving pharmaceutical and biotechnology companies. John's technical expertise is grounded in biochemistry, particularly drug mechanisms of action, and extends into chemicals, chemical processes, molecular diagnostics, and biofuels, allowing him to work well with experts in a variety of fields.
John also has rendered opinions involving infringement and validity directed to pharmaceutical and chemical subject matter, and counseled a pharmaceutical company regarding the development of a patent portfolio.
- Counsel for one of the world's largest biotechnology companies in a patent infringement case.
- Counsel for a foreign molecular diagnostic company in a patent infringement case.
- Counsel for foreign and domestic pharmaceutical companies in district court patent litigations under the Hatch-Waxman Act.
- Counsel for the world's largest veterinary pharmaceutical company in district court patent litigations, including contempt hearings.
- Counsel for a foreign pharmaceutical company regarding pre-litigation matters concerning litigation under the Hatch-Waxman Act.
- Provides patent-related counseling to various pharmaceutical and chemical companies.
- Represented a leader in biotechnology-based fuels in a complex trade secret matter.
- Developed a patent portfolio directed to disease treatments by drafting a series of patent applications and providing strategic counseling to a pharmaceutical company.
- Lectures on the practice of intellectual property law and protection of U.S. patent rights at various universities, law schools and meetings of the American Chemical Society, including moderating panels and speaking at BIO Intellectual Property Counsel's Committee meetings.
John Cox, counsel in the firm’s Intellectual Property Litigation Group, was quoted in Specialty Pharmacy News discussing the Myriad Genetics Supreme Court decision, which declared that naturally occurring DNA cannot be patented, and how that decision may stifle innovation in genetic testing.
July 1, 2013
In the Press